However, the emergence of chemoresistance, peripheral neuropathy, nephrotoxicity, and hepatorenal toxicity to paclitaxel has posed significant challenges in cervical cancer treatment.[42] Here we showed that silence of either lncTUBA3FP or ESCO1 enhanced the sensitivity of cervical cancer cells to paclitaxel, as evidenced by reduced tumorigenesis and increased ferroptosis levels. Here, ESCO1 is linked to peripheral neuropathy.